Abstract
The correlates of protective immunity in HIV-1 infection include the endogenous production of compounds with anti-HIV-1 activity. These compounds can be produced independently of specific humoral or cellular immune responses. A model of compartmental inhibition of HIV-1 infection is the placenta, an organ that prevents transmission of HIV-1 to the fetus in the majority of HIV-1 pregnancies. Studies of this organ elucidated new compounds and mechanisms for prevention and treatment of HIV including the potent inhibitor of HIV-1, leukemia inhibitory factor (LIF). Besides coordinating the humoral and cellular immune responses, cytokines such as IFN-? exhibit intrinsic antiviral activity that represents the first line of defense against pathogens prior to the development of a specific immune response. The study of antiviral factors is particularly important in HIV / AIDS because of the direct destruction of the immune system by HIV-1. In this report, we focus on the identification and mechanism of endogenously produced anti-HIV factors and the overall function of these factors in the prevention and treatment of HIV / AIDS.
Keywords: hiv, lif, cytokines, jak, stat, reverse transcription, transcription, placenta
Current Molecular Medicine
Title: Endogenous Inhibitors of HIV: Potent Anti-HIV Activity of Leukemia Inhibitory Factor
Volume: 2 Issue: 8
Author(s): B. K. Patterson, A. Tjernlund and J. Andersson
Affiliation:
Keywords: hiv, lif, cytokines, jak, stat, reverse transcription, transcription, placenta
Abstract: The correlates of protective immunity in HIV-1 infection include the endogenous production of compounds with anti-HIV-1 activity. These compounds can be produced independently of specific humoral or cellular immune responses. A model of compartmental inhibition of HIV-1 infection is the placenta, an organ that prevents transmission of HIV-1 to the fetus in the majority of HIV-1 pregnancies. Studies of this organ elucidated new compounds and mechanisms for prevention and treatment of HIV including the potent inhibitor of HIV-1, leukemia inhibitory factor (LIF). Besides coordinating the humoral and cellular immune responses, cytokines such as IFN-? exhibit intrinsic antiviral activity that represents the first line of defense against pathogens prior to the development of a specific immune response. The study of antiviral factors is particularly important in HIV / AIDS because of the direct destruction of the immune system by HIV-1. In this report, we focus on the identification and mechanism of endogenously produced anti-HIV factors and the overall function of these factors in the prevention and treatment of HIV / AIDS.
Export Options
About this article
Cite this article as:
Patterson K. B., Tjernlund A. and Andersson J., Endogenous Inhibitors of HIV: Potent Anti-HIV Activity of Leukemia Inhibitory Factor, Current Molecular Medicine 2002; 2 (8) . https://dx.doi.org/10.2174/1566524023361817
DOI https://dx.doi.org/10.2174/1566524023361817 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Toll Pathways in Viral Respiratory Disease During Early Childhood
Current Molecular Medicine Soft Condensed Matter in Pharmaceutical Design
Current Pharmaceutical Design Adenovirus/PSA (Ad5-PSA) Vaccination for Prostate Cancer: Pre-Clinical and Clinical Development
Current Cancer Therapy Reviews Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance
Current Drug Targets Fight Against H1N1 Influenza A Virus: Recent Insights Towards the Development of Druggable Compounds
Current Medicinal Chemistry Editorial [Pharmacogenovigilance – An Idea whose Time has Come]
Current Pharmacogenomics and Personalized Medicine Targeting Soluble Epoxide Hydrolase for Inflammation and Pain - An Overview of Pharmacology and the Inhibitors
Inflammation & Allergy - Drug Targets (Discontinued) P2X Receptors in the Cardiovascular System and their Potential as Therapeutic Targets in Disease
Current Medicinal Chemistry Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL
Current Drug Targets Deubiquitinating Enzymes as Promising Drug Targets for Infectious Diseases
Current Pharmaceutical Design Second Generation Abl Kinase Inhibitors and Novel Compounds to Eliminate the Bcr-Abl/T315I Clone
Recent Patents on Anti-Cancer Drug Discovery An Overview on Immunity Booster Foods in Coronavirus Disease (COVID-19)
Combinatorial Chemistry & High Throughput Screening Metals and Parkinson's Disease: Mechanisms and Biochemical Processes
Current Medicinal Chemistry Murine Skin-resident γδT Cells Impair the Immune Response to HSV in Skin
Infectious Disorders - Drug Targets Leptin, Immune Responses and Autoimmune Disease. Perspectives on the Use of Leptin Antagonists
Current Pharmaceutical Design Post-Stroke Immunodepression and Infection: An Emerging Concept
Infectious Disorders - Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Porphyrin-Photosensitized Processes: Their Applications in the Prevention of Arterial Restenosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics The Central Role Played by Peptides in the Immune Response and the Design of Peptide-Based Vaccines Against Infectious Diseases and Cancer
Current Drug Targets